Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Methotrexate 11Busulfan 11Cytarabine 10fludarabine 8Daunorubicin 8Cyclophosphamide 8fludarabine phosphate 7Whole-Body Irradiation 7Etoposide 7Tacrolimus 6Mitoxantrone 5Melphalan 5Idarubicin 5Thioguanine 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Azacitidine 4thymoglobulin 3Radiotherapy 3Filgrastim 3Early Intervention, Educational 3Decitabine 3Cyclosporine 3Asparaginase 3Antilymphocyte Serum 3merphos 2luspatercept 2decitabine and cedazuridine drug combination 2Tretinoin 2Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Myelodysplastic Syndromes × lonafarnib × Clear all
NCT00109538 2015-05-01

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 3 Terminated
47 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡